Brogan AJ, Talbird SE, Davis AE, Wild L, Flanagan D. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV Med. 2019 Nov;20(10):668-80. doi: 10.1111/hiv.12788
Song LD, Newhouse JP, Garcia-De-Albeniz X, Hsu J. Changes in screening colonoscopy following Medicare reimbursement and cost-sharing changes. Health Serv Res. 2019 Aug;54(4):839-50. doi: 10.1111/1475-6773.13150
Hillemeier MM, Domino ME, Wells R, Goyal RK, Kum HC, Cilenti D, Basu A. Does maternity care coordination influence perinatal health care utilization? Evidence from North Carolina. Health Serv Res. 2018 Aug;53(4):2368-83. doi: 10.1111/1475-6773.12742
Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV Med. 2016 Aug;17(7):505-15. doi: 10.1111/hiv.12349
Franzini L, White C, Taychakhoonavudh S, Parikh R, Zezza M, Mikhail O. Variation in inpatient hospital prices and outpatient service quantities drive geographic differences in private spending in Texas. Health Serv Res. 2014 Dec;49(6):1944-63. doi: 10.1111/1475-6773.12192
Richter A, Pladevall M, Manjunath R, Lafata JE, Xi H, Simpkins J, Brar I, Markowitz N, Iloeje U, Irish W. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med. 2005 Mar 1;6(2):79-90.